PEDIATRICS Vol. 75 No. 3 March 1985, pp. 501-507
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Usberti, M.
Right arrow Articles by Carbonaro, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Usberti, M.
Right arrow Articles by Carbonaro, L.

Mechanism of Action of Indomethacin in Tubular Defects

Mario Usberti MD1, Carmine Pecoraro MD1, Stefano Federico MD1, Bruno Cianciaruso MD1, Bruna Guida MD1, Anna Romano MD1, Lucia Grumetto MD1, and Lucia Carbonaro MD1

1 From the Cattedra di Nefrologia Medica, Clinica Pediatrica, II Facoltà di Medicina e Chirurgia, Università di Napoli, Napoli Italy

Indomethacin, a potent prostaglandin synthesis inhibitor, has been proven to be effective in a number of tubular defects characterized by enhanced prostaglandin (namely, prostaglandin E2 (PGE2) production, but its mechanism of action is poorly understood. To elucidate further the mechanism(s) by which indomethacin reverses the abnormal tubular functions, five children with different tubular defects (nephrogenic diabetes insipidus, three cases; Fanconi syndrome, one case; and pseudohypoaldosteronism, one case) were treated with indomethacin. Indomethacin, 1 mg/kg every eight hours, was given for 1 week to all children and then was given chronically to four of the children who responded to the drug. Its use was suspended in a 10 year-old-boy with nephrogenic diabetes insipidus because it proved ineffective. To assess the site along the nephron where indomethacin affects the solute and water excretion, an acute water load study was performed in three responsive children before and during the treatment. Indomethacin did not significantly alter the glomerular filtration rate but was effective in reducing diuresis and levels of urinary sodium and potassium excretion. In the child with Fanconi syndrome, indomethacin was also effective in controlling the urinary loss of phosphate, urate, glucose, and bicarbonate. Results of the water load studies show that indomethacin decreases the delivery of solute from the proximal tubule, reduces the fractional free water clearance, and increases the urine-plasma osmolar ratio. The rate of urinary excretion of prostaglandin E2 was high in all five children; it decreased below normal values in four of them after 1 week of treatment. In the child with nephrogenic diabetes insipidus who did not respond to indomethacin therapy, prostaglandin E2 excretion decreased but the rate remained higher than normal. These results suggest that indomethacin induces retention of solute and water mainly through an enhanced proximal tubular reabsorption.

Key Words: indomethacin • tubular defects

Submitted on February 14, 1984
Accepted on April 4, 1984




This article has been cited by other articles:


Home page
 CLIN PEDIATRHome page
N. Watemberg and H. Shalev
Daytime Urinary Frequency in Children
Clinical Pediatrics, January 1, 1994; 33(1): 50 - 53.
[PDF]

Home page
 CLIN PEDIATRHome page
P. M. Mathew, K. B. Manasra, and J. A. Hamdan
Indomethacin and Cation-Exchange Resin in The Management of Pseudohypoaldosteronism
Clinical Pediatrics, January 1, 1993; 32(1): 58 - 60.
[PDF]